Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Abstract The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is be...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-02-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13045-019-0703-z |
| _version_ | 1818893593641746432 |
|---|---|
| author | Delong Liu Juanjuan Zhao Yongping Song Xiaofeng Luo Ting Yang |
| author_facet | Delong Liu Juanjuan Zhao Yongping Song Xiaofeng Luo Ting Yang |
| author_sort | Delong Liu |
| collection | DOAJ |
| description | Abstract The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made. In addition to the tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, immunotherapeutic agents, blinatumomab, inotuzumab ozogamicin (INO), and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being incorporated into induction chemotherapy regimens and combined with TKIs for ALL therapy. A novel low-intensity regimen, miniHCVD-INO-blinatumomab, appears to be less toxic and more effective than conventional intensive chemotherapy regimens. This review summarized new therapeutic researches of ALL and updated latest progress in clinical trials on bispecific antibodies, antibody-drug conjugates, and new regimens incorporating these novel antibodies. |
| first_indexed | 2024-12-19T18:15:04Z |
| format | Article |
| id | doaj.art-3b67a551f7a34676a380a7c1de9f106c |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-19T18:15:04Z |
| publishDate | 2019-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-3b67a551f7a34676a380a7c1de9f106c2022-12-21T20:11:08ZengBMCJournal of Hematology & Oncology1756-87222019-02-0112111310.1186/s13045-019-0703-zClinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemiaDelong Liu0Juanjuan Zhao1Yongping Song2Xiaofeng Luo3Ting Yang4Department of Oncology, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer HospitalDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer HospitalDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union HospitalDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union HospitalAbstract The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made. In addition to the tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, immunotherapeutic agents, blinatumomab, inotuzumab ozogamicin (INO), and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being incorporated into induction chemotherapy regimens and combined with TKIs for ALL therapy. A novel low-intensity regimen, miniHCVD-INO-blinatumomab, appears to be less toxic and more effective than conventional intensive chemotherapy regimens. This review summarized new therapeutic researches of ALL and updated latest progress in clinical trials on bispecific antibodies, antibody-drug conjugates, and new regimens incorporating these novel antibodies.http://link.springer.com/article/10.1186/s13045-019-0703-zAcute lymphoblastic leukemiaBispecific antibodyAntibody-drug conjugateChimeric antigen receptorHyper-CVAD |
| spellingShingle | Delong Liu Juanjuan Zhao Yongping Song Xiaofeng Luo Ting Yang Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia Journal of Hematology & Oncology Acute lymphoblastic leukemia Bispecific antibody Antibody-drug conjugate Chimeric antigen receptor Hyper-CVAD |
| title | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
| title_full | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
| title_fullStr | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
| title_full_unstemmed | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
| title_short | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia |
| title_sort | clinical trial update on bispecific antibodies antibody drug conjugates and antibody containing regimens for acute lymphoblastic leukemia |
| topic | Acute lymphoblastic leukemia Bispecific antibody Antibody-drug conjugate Chimeric antigen receptor Hyper-CVAD |
| url | http://link.springer.com/article/10.1186/s13045-019-0703-z |
| work_keys_str_mv | AT delongliu clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT juanjuanzhao clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT yongpingsong clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT xiaofengluo clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia AT tingyang clinicaltrialupdateonbispecificantibodiesantibodydrugconjugatesandantibodycontainingregimensforacutelymphoblasticleukemia |